Not yet recruiting
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole
2025-524995-53-00· Phase 4· UZ Brussel· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242· Phase 3· Avidity Biosciences, Inc.· Source
Contact: Avidity Bioscience, Inc., A Novartis Company
Not yet recruiting
A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study
2026-526241-98-00· Phase 2· Kymera Therapeutics Inc.· Source
Recruiting
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
NCT07630714· Phase 2· AstraZeneca· Source
Not yet recruiting
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
NCT07682129· Phase 2· Entrada Therapeutics, Inc.· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00· Phase 3· Avidity Biosciences Inc.· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· Phase 2· Verastem, Inc.· Source
Recruiting
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
NCT07656415· Phase 3· Agios Pharmaceuticals, Inc.· Source
Recruiting
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07673627· Phase 2· argenx· Source
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
NCT07675135· Phase 3· Harmony Biosciences Management, Inc.· Source
Recruiting
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
NCT07554495· Phase 3· Alfasigma S.p.A.· Source
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934· Phase 3· Dyne Therapeutics· Source
Recruiting
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma
2025-523180-38-00· Phase 2· Kymera Therapeutics Inc.· Source
Recruiting
OLE Study With Filgotinib in JIA
NCT07553182· Phase 3· Alfasigma S.p.A.· Source
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459· Phase 2· Contineum Therapeutics· Source
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420· Phase 2· argenx· Source
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
2024-520130-29-00· Phase 2· Scholar Rock Inc.· Source
Active, not recruiting
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189· Phase 2· Satellos Bioscience, Inc.· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· Phase 3· Amgen Inc.· Source
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· Phase 3· ImmunityBio, Inc.· Source
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417· Phase 3· Alfasigma S.p.A.· Source
Contact: Marie Leonard, MD
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
NCT07038824· Phase 1/2· Entrada Therapeutics, Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
2024-517529-26-00· Phase 3· Dianthus Therapeutics Inc.· Source
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519· Phase 3· AbbVie· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
NCT07037862· Phase 1/2· Entrada Therapeutics, Inc.· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· Phase 3· GlaxoSmithKline· Source
Recruiting
A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis
2024-511458-32-00· Phase 3· Alfasigma S.p.A.· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· Phase 2· Pfizer· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970· Phase 2· Agios Pharmaceuticals, Inc.· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2024-518343-38-00· Phase 3· Alnylam Pharmaceuticals Inc.· Source
Active, not recruiting
An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma
2024-512113-41-00· Phase 3· AstraZeneca AB· Source
Active, not recruiting
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955· Phase 2· BioAegis Therapeutics Inc.· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279· Phase 3· argenx· Source
Active, not recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534· Phase 3· AbbVie· Source
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323· Phase 3· GlaxoSmithKline· Source
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Active, not recruiting
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· Phase 3· AstraZeneca· Source
Recruiting
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT06262438· Phase 2· Princess Maxima Center for Pediatric Oncology· Source
Recruiting
Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention
NCT06095765· Phase 3· AZ Sint-Jan AV· Source
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629· Phase 3· Intellia Therapeutics· Source
Showing 50 of 96.